AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, oncology and neuroscience – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Pictured: Pre-filled injector device/iStock, sunny

First Round of Humira Biosimilar Launches in US

AbbVie’s Humira will now face competition from new biosimilars, including Boehringer Ingelheim’s Cyltezo, Celltrion’s Yuflyma, Organon and Samsung’s Hadlima, and Sandoz’s Hyrimoz.

July 3, 2023

2 min read

Tristan Manalac

Pictured: AbbVie sign on a building/courtesy of Ad

Drug Development

AbbVie, Genmab Bi-Specific Lymphoma Data Tee Up Potential Challenge to Roche Drug

Phase I/II data on AbbVie and Genmab’s recently approved bi-specific antibody in a second cancer indication positions them to talk to regulators about filings to challenge Roche’s Lunsumio.

June 29, 2023

2 min read

Nick Paul Taylor

Pictured: Analyst pointing to stock chart / iStock

Drug Development

MoonLake Looks to Raise $250M in Stock Offering on Heels of Mid-Stage Data

Phase II results of MoonLake’s sonelokimab suggest superiority to the competition. Funds raised in the stock offering will support Phase III trials with an anticipated launch in 2027.

June 27, 2023

2 min read

Kate Goodwin

Pictured: T cells attacking and killing cancer cel

FDA

Roche, AbbVie to Compete for Lymphoma Market Share with New BsAbs

With Roche’s FDA approval on Thursday, both companies’ bispecific antibodies will hit the market this summer for relapsed or refractory diffuse large B-cell lymphoma.

June 16, 2023

3 min read

Kate Goodwin

Pictured: Judicial gavel and scales of justice/Cou

Policy

AbbVie Files Patent Infringement Lawsuit Against BeiGene’s Brukinsa

The pharma company alleges that BeiGene’s Brukinsa patent, issued on Tuesday, infringes on its patent for Imbruvica to treat patients with slow-growing blood cancer.

June 15, 2023

2 min read

Alejandra Manjarrez

Pictured: Mark Cuban/Courtesy of Roy Rochlin/Getty

Business

Coherus to Offer 85% Discount for its Humira Biosimilar

The company’s Humira biosimilar Yusimry will launch in July with a $995 list price. Mark Cuban’s online pharmacy will sell it at a list price of $569.27 plus fees.

June 2, 2023

2 min read

Tristan Manalac

Pictured: Blue and white Pfizer sign on building/c

Drug Development

Pfizer’s Antibiotic Combo Clears Phase III, Shows Promise Against Multidrug Resistance

The company’s aztreonam-avibactam matched the cure rate of a meropenem-based regimen in patients with drug-resistant infections.

June 2, 2023

3 min read

Tristan Manalac

Drug Development

AbbVie’s Rinvoq Maintains Durability in Phase II Lupus Study

The company’s blockbuster JAK inhibitor, alone or as a combination therapy, showed durable improvements in systemic lupus erythematosus disease activity at 48 weeks.

May 31, 2023

3 min read

Heather McKenzie

FDA

AbbVie, Genmab Score FDA Nod for DLBCL as Blood Cancer Space Heats Up

With Friday’s approval, Epkinly edges out Roche’s bi-specific antibody glofitamab, which is also being proposed for diffuse large B-cell lymphoma.

May 22, 2023

2 min read

Tristan Manalac

JOBS